Highs and lows of iPSC funding

Funding for companies developing iPSC-derived cell therapies began to pick up in 2019 as clinical proof of concept started to emerge, and momentum across the broader cell and gene therapy field propelled the technology forward.

Funding levels have dropped sharply from the 2021 peak, however, likely due to the combination of bear market forces and durability concerns for a leading iPSC application — NK cell therapy — that led several companies to restructure and deprioritize certain iPSC programs...